Lansoprazole , ≥98% , 103577-45-3
Synonym(s):
2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl] methyl] sulfinyl]-1H-benzimidazole;LAN;Lansoprazole
CAS NO.:103577-45-3
Empirical Formula: C16H14F3N3O2S
Molecular Weight: 369.36
MDL number: MFCD00866873
EINECS: 2017-001-1
| Pack Size | Price | Stock | Quantity |
| 250MG | RMB42.40 | In Stock |
|
| 1G | RMB45.60 | In Stock |
|
| 5G | RMB92.80 | In Stock |
|
| 25G | RMB351.20 | In Stock |
|
| 100G | RMB1342.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 178-182°C dec. |
| Boiling point: | 555.8±60.0 °C(Predicted) |
| Density | 1.50±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | Practically insoluble in water, soluble in anhydrous ethanol, very slightly soluble in acetonitrile. |
| pka | pKa 2.34±0.37 (Occasionally);3.53±0.37 (Occasionally);8.48±0.30 (Occasionally) |
| form | powder |
| color | off-white |
| Merck | 14,5362 |
| BCS Class | 2 |
| InChI | InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) |
| InChIKey | MJIHNNLFOKEZEW-UHFFFAOYSA-N |
| SMILES | C1(S(CC2=NC=CC(OCC(F)(F)F)=C2C)=O)NC2=CC=CC=C2N=1 |
| CAS DataBase Reference | 103577-45-3(CAS DataBase Reference) |
Description and Uses
Lansoprazole is a proton pump inhibitor that inhibits the H+/K+-ATPase. It inhibits K+ and H+ accumulation in gastric microsomes in a concentration-dependent manner (IC50s = 6.3 and 7.0 μM, respectively) and inhibits H+/K+-ATPase activity by approximately 60% when used at a concentration of 10 μM. Lansoprazole inhibits the H+/K+-ATPase in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH. It is a substituted benzimidazole that binds covalently to proton pumps, providing complete and prolonged inhibition of acid secretion. Formulations containing lansoprazole have been used as a proton pump inhibitor and in combination with antibiotics in the treatment of H. pylori infections and duodenal ulcer disease.
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Safety
| Symbol(GHS) | ![]() GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P261-P264-P271-P280-P302+P352-P305+P351+P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| WGK Germany | 2 |
| RTECS | DD9487500 |
| HS Code | 29339900 |
| Hazardous Substances Data | 103577-45-3(Hazardous Substances Data) |
| Toxicity | dog,LD,oral,> 2gm/kg (2000mg/kg),Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 387, 1993. |







